Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03595618 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis
A Phase 2 study, sponsored by Lakefront Biotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 932
- Enrollment target
NCT03595618: Completed Phase 2 study, sponsored by Lakefront Biotherapeutics.
NCT03595618 is a Phase 2 study that has completed, run by Lakefront Biotherapeutics. The registered enrollment target is 932 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (601% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03595618, a Phase 2 study, has completed, sponsored by Lakefront Biotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 932 participants
- Enrollment target
Study Summary
This study is a phase 2, 52-week international, multi-regional, multi-center, randomized, double-blind, placebo-controlled dose-ranging study for the treatment of osteoarthritis.
Primary Outcome
Reduction in cartilage loss was assessed by cartilage thickness as measured in the medial cMTFC of the target knee using qMRI.
Interventions
- DRUG Placebo
- DRUG GLPG1972
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 932 participants |
| Start Date | 2018-08-14 |
| Est. Completion | 2020-07-14 |
| Phase | Phase 2 |
What the finished NCT03595618 record still lists
NCT03595618 is an interventional study that assigns participants to a tested intervention. The registered 932 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (601% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03595618 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03595618 about?
NCT03595618 is a clinical study titled "A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis". This study is a phase 2, 52-week international, multi-regional, multi-center, randomized, double-blind, placebo-controlled dose-ranging study for the treatment of osteoarthritis.
What is the current status of trial NCT03595618?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 932 participants. The study started on 2018-08-14. Estimated completion is 2020-07-14.
What interventions are being tested in trial NCT03595618?
The interventions under investigation include: Placebo (DRUG), GLPG1972 (DRUG).
Who is sponsoring clinical trial NCT03595618?
This trial is sponsored by Lakefront Biotherapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03595618's enrollment target sits among peer trials
932 29th of 2000 higher than 1,972 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04626635 · 933 participants · Phase 1
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
- NCT05216432 · 930 participants · Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- NCT06932029 · 930 participants · NA
SMBP Study: Improving High Blood Pressure in Older Adults With Multiple Chronic Diseases
- NCT07235085 · 930 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI